The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical impact of mutations in driver oncogenes and TP53/RB1 in advanced prostate cancer.
 
Liat Hammer
No Relationships to Disclose
 
Ryan Rebernick
No Relationships to Disclose
 
Matthew McFarlane
No Relationships to Disclose
 
Thomas Westbrook
No Relationships to Disclose
 
Munna Hazime
No Relationships to Disclose
 
Tanya Hammoud
No Relationships to Disclose
 
Pin-en Chiu
No Relationships to Disclose
 
Owens Xavier
No Relationships to Disclose
 
Yi-Mi Wu
No Relationships to Disclose
 
Dan R. Robinson
No Relationships to Disclose
 
Daniel Eidelberg Spratt
Honoraria - Varian Medical Systems
Consulting or Advisory Role - AstraZeneca; Bayer; Blue Earth Diagnostics; Boston Scientific; Janssen Oncology; Varian Medical Systems
Research Funding - Janssen (Inst)
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; BMS; Merck; Pfizer
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Merck
 
William C. Jackson
No Relationships to Disclose
 
Zachery R Reichert
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
 
Joshi J. Alumkal
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene
Research Funding - Beactica (Inst); Zenith Epigenetics (Inst)
 
Arul Chinnaiyan
Stock and Other Ownership Interests - Esanik; LynxDx; Oncopia Therapeutics; Tempus
Honoraria - BMS
Consulting or Advisory Role - Ascentage Pharma; EdenRoc Sciences; Esanik; LynxDX; Oncopia Therapeutics; Rappta Therapeutics; Tempus
Patents, Royalties, Other Intellectual Property - University of Michigan Patents
 
Marcin Cieslik
No Relationships to Disclose
 
Robert Timothy Dess
No Relationships to Disclose